Nrf2 and Redox Status in Prediabetic and Diabetic Patients

Jiménez-Osorio, Angélica Saraí; Picazo, Alejandra; González-Reyes, Susana; Barrera-Oviedo, Diana; Rodríguez-Arellano, Martha Eunice; Pedraza‐Chaverrí, José

doi:10.3390/ijms151120290

Cited by 88 publications

(74 citation statements)

References 47 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been clinically demonstrated that there is a down-regulation of Nrf2 expression (mRNA and protein) in kidney biopsy [64], peripheral blood mononuclear cells (PBMC) [62,66] and skin tissue (foot ulcer and gangrene) in diabetics [67]. In fact, our group found decreased nuclear Nrf2 in PBMC obtained from prediabetics [66].…”

Section: Nrf2 In Prediabetes and Diabetesmentioning

confidence: 54%

See 1 more Smart Citation

Natural Nrf2 activators in diabetes

Jiménez-Osorio

González-Reyes

Pedraza‐Chaverrí

2015

Clinica Chimica Acta

Self Cite

127

View full text Add to dashboard Cite

Section: Nrf2 In Prediabetes and Diabetesmentioning

confidence: 54%

“…In fact, our group found decreased nuclear Nrf2 in PBMC obtained from prediabetics [66]. Together, these studies have shown that Nrf2 down-regulation during chronic hyperglycemia could be an important target for treatment.…”

Section: Nrf2 In Prediabetes and Diabetesmentioning

confidence: 94%

Natural Nrf2 activators in diabetes

Jiménez-Osorio

González-Reyes

Pedraza‐Chaverrí

2015

Clinica Chimica Acta

Self Cite

127

View full text Add to dashboard Cite

“…Data were expressed as k/mg protein. SOD activity was determined by its ability to prevent formazan production from the reaction of NBT and superoxide anion (O ÁÀ 2 ) generated by the xanthine-xanthine oxidase system [41]. One hundred and fifty lg of mitochondrial protein or 50 mM phosphate buffer pH 7.0 (100 % formazan production) were added to the reaction mixture with the following composition: 90 lM xanthine, 16 mM Na 2 CO 3 , 2 mM KCN, 22.8 lM NBT, and 18 mM phosphate buffer; pH 7.0.…”

Section: Activity Of Antioxidant Enzymesmentioning

confidence: 99%

C-phycocyanin prevents cisplatin-induced mitochondrial dysfunction and oxidative stress

et al. 2015

Self Cite

View full text Add to dashboard Cite

The potential of C-phycocyanin (C-PC) to prevent cisplatin (CP)-induced kidney mitochondrial dysfunction was determined in CD-1 male mice. The CP-induced mitochondrial dysfunction was characterized by ultrastructural abnormalities and by decrease in the following parameters in isolated kidney mitochondria: adenosine diphosphate (ADP)-induced oxygen consumption (state 3), respiratory control ratio, ADP/oxygen (ADP/O) ratio, adenosine triphosphate synthesis, membrane potential, calcium retention, glutathione (GSH) content, and activity of respiratory complex I, aconitase, catalase, and GSH peroxidase. These mitochondria also showed increase in hydrogen peroxide production, malondialdehyde, and 3-nitrotyrosine protein adducts content. The above-described changes, as well as CP-induced nephrotoxicity, were attenuated in mice pretreated with a single injection of C-PC. Our data suggest that the attenuation of mitochondrial abnormalities is involved in the protective effect of C-PC against CP-induced nephrotoxicity. This is the first demonstration that C-PC pretreatment prevents CP-induced mitochondrial dysfunction in mice.

show abstract

“…Studies, summarized in Table 5, show also that Type 2 DM is a condition of increased oxidative stress [44,45,103,[107][108][109].…”

Section: -Chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)mentioning

confidence: 99%

Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Choi

2017

Redox Report

View full text Add to dashboard Cite

Objectives: This is a narrative review, investigating the antioxidant properties of drugs used in the management of diabetes, and discusses whether these antioxidant effects contribute to, confound, or conceal the effects of antioxidant therapy. Methods: A systematic search for articles reporting trials, or observational studies on the antioxidant effect of drugs used in the treatment of diabetes in humans or animals was performed using Web of Science, PubMed, and Ovid. Data were extracted, including data on a number of subjects, type of treatment (and duration) received, and primary and secondary outcomes. The primary outcomes were reporting on changes in biomarkers of antioxidants concentrations and secondary outcomes were reporting on changes in biomarkers of oxidative stress. Results: Diabetes Mellitus is a disease characterized by increased oxidative stress. It is often accompanied by a spectrum of other metabolic disturbances, including elevated plasma lipids, elevated uric acid, hypertension, endothelial dysfunction, and central obesity. This review shows evidence that some of the drugs in diabetes management have both in vivo and in vitro antioxidant properties through mechanisms such as scavenging free radicals and upregulating antioxidant gene expression. Conclusion: Pharmaceutical agents used in the treatment of type 2 diabetes has been shown to exert an antioxidant effect..

show abstract

Nrf2 and Redox Status in Prediabetic and Diabetic Patients

Cited by 88 publications

References 47 publications

Natural Nrf2 activators in diabetes

Natural Nrf2 activators in diabetes

C-phycocyanin prevents cisplatin-induced mitochondrial dysfunction and oxidative stress

Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Contact Info

Product

Resources

About